{"id":19037,"date":"2022-01-14T12:06:50","date_gmt":"2022-01-14T11:06:50","guid":{"rendered":"https:\/\/www.idisantiago.es\/grupo-de-investigacion\/c020-genetica-vacunas-infecciones-y-pediatria-genvip\/"},"modified":"2026-01-23T15:13:12","modified_gmt":"2026-01-23T14:13:12","slug":"c020-genetica-vacunas-infecciones-y-pediatria-genvip","status":"publish","type":"project","link":"https:\/\/www.idisantiago.es\/en\/grupo-de-investigacion\/c020-genetica-vacunas-infecciones-y-pediatria-genvip\/","title":{"rendered":"C020 – Genetics, Vaccines, Infections and Pediatrics (GENVIP)"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||||false|false” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” custom_padding=”0px||||false|false” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”]AREA: INFECTOLOGY, INFLAMMATION AND VACCINES<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.idisantiago.es\/wp-content\/uploads\/2022\/02\/GRUPO-C020-scaled.jpg” title_text=”GRUPO C020″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_toggle title=”Objectives and lines of research” admin_label=”Objetivos y l\u00edneas de investigaci\u00f3n” _builder_version=”4.19.4″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n

Objectives<\/h3>\n

GENVIP is made up of a multidisciplinary team of a transversal nature in the field of basic and applied clinical research<\/strong> that uses the latest technologies and analytical methods from different disciplines to optimize the treatment of pediatric patients. The group is made up of experts in different areas of biomedical research (doctors, nurses, pharmacists, geneticists, biologists, mathematicians, and bioinformaticians), who provide a broad and global perspective.
GENVIP’s mission is to advance knowledge of the genetic bases of pediatric infections and contribute to the development of individualized prevention and treatment strategies.<\/strong> The team is led by Professor Federico Martin\u00f3n-Torres (Head of the Pediatric Service of the University Hospital Complex of Santiago and Head of Pediatrics at the University of Santiago), pediatrician with experience in the clinical area and in research in the field of infectious diseases.
The main potential of the group is the combination and integration of the different views on problems related to health, with the ultimate goal of obtaining the best result for the patient. Thus, due to its experience in the study and management of viral and bacterial infections, the scientific activity of the group is basically translated into the field of pediatric health, mainly through:
\u2022 development of individualized action strategies in treatment or prevention<\/strong>
\u2022 development of new tools for the detection of biological markers<\/strong> for application in diagnosis and\/or prognosis.
\u2022 identification of new therapeutic targets<\/strong>
GENVIP has created a Clinical Trials Unit focused mainly on the area of \u200b\u200bvaccines. This unit channels a large part of the clinical trials carried out in Spain on pediatric vaccines, from phases 1 to 3. In addition, it collaborates with various promoters in the design of protocols and clinical development programs for various vaccine candidates.<\/p>\n

Lines of research<\/h3>\n

Among our most notable RESEARCH AREAS are the following:
\u2022 ‘Omics’ applied to infectious diseases in pediatrics<\/strong>: the main objective of the group is to deepen the knowledge of the pathogenesis of diseases that affect children from different perspectives, through an ‘-omics’ approach. This approach, which involves multiple ‘-omics’ tools (transcriptomics, genomics, epigenomics, etc.), can help to understand the different molecular mechanisms underlying the host response to infection and explore, from various perspectives, whether genomic biomarkers exist. , transcriptomic and \/ or epigenetic that may be related to the diagnosis, prognosis and evolution of the infection. The GENVIP team has extensive experience in the translational approach to infectious diseases and its applicability for the benefit of the patient. In this regard, GENVIP has contributed with several translational projects to the development of diagnostic tests based on host responses to infection. The study of infectious diseases at GENVIP not only implies stable lines of research in the field, but also includes numerous collaborations with international reference centers such as Imperial College London, Ospedale Pediatrico Bambino Gesu, PENTA Fondazione, the Genomic Institute of Singapore , Rabdoud University, Oxford Gene Technology, ReSVinet, Genomic Systems or the National Children’s Hospital of Ohio, among others, as well as with the main Spanish pediatric reference hospitals. GENVIP directs and coordinates numerous national and international multi-centre clinical networks in charge of obtaining samples from patients with different pathologies that affect the pediatric age.<\/p>\n

\u2022 Vaccinomics and immunogenomics<\/strong>: applying the omic approach to the study of vaccines helps us better understand the individual’s response to the different vaccine antigens, discover new protection markers and establish individualized protection strategies through vaccination. The study of its heterologous properties is another of the lines that GENVIP is active in the field of vaccines, specifically focused on BCG, rotavirus and pneumococcal vaccines, but also developing the appropriate models to apply the paradigm to other new vaccines. GENVIP collaborates directly with the World Health Organization (WHO) in Europe in scheduled interventions and acute crises in the field of vaccines and infectious diseases as a WHO Collaborating Center for Vaccine Safety.<\/p>\n

\u2022 Bioinformatics and data analysis:<\/strong> the GENVIP group has experts in biology \/ genetics, bioinformatics and mathematics \/ statistics with extensive experience in handling genomic, transcriptomic and epigenomic data from high-throughput platforms and Next Generation Sequencing. Within the group, computer applications have been developed, some internal lines for the analysis of genomic \/ transcriptomic data and predictive bioinformatic models applied to different pathologies.<\/p>\n

\u2022 Rare childhood diseases<\/strong>: GENVIP has a line of research focused on the study of Progressive Bone Heteroplasia (POH) and heterotopic ossification. PH is an ultra-rare disease that causes extra-skeletal bone formation from mesodermal tissue. There is no effective or preventive treatment for this disease. Using a translational “-omic” approach, we are trying to characterize the disease and identify therapeutic targets that allow us to improve the quality of life of patients.<\/p>\n

\u2022 Childhood allergic diseases<\/strong>: GENVIP has several open lines of research in this direction, with active studies in pathologies such as asthma or protein-induced enterocolitis syndrome (FPIES projects), which is a common and pathophysiological type of food allergy. little known, potentially lethal, and for which there is no diagnostic test.<\/p>\n

 <\/p>\n

[\/et_pb_toggle][et_pb_toggle title=”Research team” admin_label=”Equipo investigador” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n\n\n\n\n
Leader<\/strong>
Martin\u00f3n Torres, Federico<\/p>\n

 <\/p>\n

Coleader\u00a0<\/strong>
Rivero Calle, Irene<\/p>\n

 <\/p>\n

Members<\/strong>
\u00c1lvarez Smith, Cintia Irene
Ares G\u00f3mez, Mar\u00eda Sonia
Autr\u00e1n Garc\u00eda, Mar\u00eda Teresa
Bello Paderne, Xabier
Ben Garc\u00eda, Miriam
Bouz\u00f3n Alejandro, Marta
Caama\u00f1o Vi\u00f1a, Fernando
Carballal Fern\u00e1ndez, Alicia
Carnota Antonio, Sandra
Casas P\u00e9rez, Marina
Cerqueiro Rey, Silvia
Cotovad Bellas, Ana
Curr\u00e1s Tuala, Mar\u00eda Jos\u00e9
Delgado Garc\u00eda, \u00c1nxela Cristina
D\u00edaz Esteban, Blanca
Dur\u00e1n Su\u00e1rez, Carlos
Eir\u00eds Pu\u00f1al, Jes\u00fas
Fern\u00e1ndez-Cuesta Pe\u00f1afiel, Jose
Garc\u00eda S\u00e1nchez, Natalia
G\u00f3mez Rial, Jos\u00e9
Justicia Grande, Antonio
Lendoiro Fuentes, Marta
L\u00f3pez Franco, Montserrat
Manzanares Casteleiro, \u00c1ngela
Marcos Alonso, Sonia
Mart\u00ednez Castro, Mar\u00eda
Mart\u00ednez Mart\u00ednez, Lara
Montero Campos, Esther
Mosquera P\u00e9rez, Bel\u00e9n
Muy P\u00e9rez, Andr\u00e9s Efra\u00edn<\/p>\n<\/td>\n

Otero Janeiro, Carlos Fernando
Pastoriza Mourelle, Ana Mar\u00eda
Pi\u00f1eiro Garc\u00eda, Antonio
Pi\u00f1eiro Rodr\u00edguez, Lidia
Prieto G\u00f3mez, Iv\u00e1n
Razzini, Josefina Lorena
Redondo Collazo, Lorenzo
Rey Garc\u00eda, Susana Mar\u00eda
Rivas Oural, Ant\u00eda
Rodr\u00edguez-Tenreiro S\u00e1nchez, Carmen
Sen\u00edn Ferreiro, Ana Mar\u00eda
Ser\u00e9n Fern\u00e1ndez, Sonia
Sobrino Fern\u00e1ndez, Mar\u00eda Elena
Talavero Gonz\u00e1lez, Cristina
V\u00e1zquez Donsi\u00f3n, Manuel
Vidal Barreiro, Raquel
Vilas Iglesias, Mar\u00eda Soledad
Viz Rodr\u00edguez, Gloria
Zhu Huang, Ouhao<\/p>\n

 <\/p>\n

External collaborators<\/strong>
\u00c1lvez Gonz\u00e1lez, Fernando
Martin\u00f3n S\u00e1nchez, Jos\u00e9 Mar\u00eda
Ser\u00e9n Trasorras, Cristina<\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/strong><\/td>\n\u00a0<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[\/et_pb_toggle][et_pb_toggle title=”Projects” admin_label=”Proyectos (cambiar s\u00f3 codigo IDIS)” _builder_version=”4.16″ _module_preset=”default” body_font=”|300|||||||” locked=”on” global_colors_info=”{}”]
\n[\/et_pb_toggle][et_pb_toggle title=”Publications” disabled_on=”off|off|off” admin_label=”Publicaciones” _builder_version=”4.16″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n